Previous 10 | Next 10 |
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update -- Regulatory guidance anticipated in the first half of 2021 for registrational clinical development plan of investigational drug, rusfertide (PTG-300), for polycythemia ver...
Protagonist is a $1.25bn market cap biotech using its peptide-based technology platform to develop a portfolio of assets targeting inflammatory conditions and cancers of the blood. Rusfertide - a hepcidin mimetic - is an exciting opportunity in Polycythemia Vera as a potential alterna...
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results PR Newswire NEWARK, Calif. , March 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), today announced it will host a conference call and webcast on ...
Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference PR Newswire NEWARK, Calif. , March 2, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel , Ph.D., President and ...
Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference PR Newswire NEWARK, Calif. , Feb. 16, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Pate...
Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire NEWARK, Calif. , Jan. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel , Ph.D., President and C...
Protagonist Therapeutics (PTGX) has dosed the first subject in a Phase 1 study evaluating PN-235 (JNJ-77242113), an oral interleukin-23 receptor antagonist peptide. The study is designed to determine the safety, tolerability and pharmacokinetics of PN-235 in ~100 healthy volunteers. Data from...
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113) NEWARK, Calif. , Dec. 16, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first subject has bee...
Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares NEWARK, Calif. , Dec. 15, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinic...
Protagonist Therapeutics (PTGX) has priced its public offering of 4,761,904 common shares at $21.00/share, for expected gross proceeds of $100M.Underwriters' over-allotment is an additional 714,285 shares.Closing date is December 15.Shares down 2% after-hours.Previously: Protagonist...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...